- Dossier admits UK biotech at breaking point.
- Sector can still flourish – but needs major investment.
- Industry calls for new investment partnership with government.
- Creation of two new investment super funds critical to future success. Ramsay Smith - Media House
According to recent information from MIND, the leading mental health charity, Patient research released today by the Healthcare Commission has revealed that a shocking 68% of mental health inpatients are still being housed on mixed sex wards, showing no improvement on last year's figures
Our eMarketing team at PharmiWeb Solutions often works with pharma brand teams to find new ways to reach healthcare professionals with news of the latest product or initiative. And sometimes, it can be challenging, with all of the pressures and time constraints that the average primary care practice faces.
We are facing a world where microbes once again have the potential to cause untreatable diseases, due to the resistance to virtually all available drugs. WHO suggests that even if the pharmaceutical industry were to step up the efforts to develop new drugs immediately, some diseases might still not have any effective therapies within the next ten years.
The global pain market generated total sales of $34bn in 2007 – but what will the figures be in the next 5 and 10 years? This report tells you.
The pain market has marked strengths and advantages, but is also limited by problems and concerns.
Suvitha Damodaran - Visiongain - Ltd
The global addiction market is significantly undervalued. The world’s population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents?
Suvitha Damodaran - Visiongain Ltd
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value.
Suvitha Damodaran - Visiongain
NHS Direct estimate that one in five UK women over forty years of age suffer from stress incontinence and, whilst it is often caused by childbirth or menopause, it can affect any women at any age.
Recent reports state that between four and five percent of the population suffer from Dyslexia. It is estimated that there are about 375,000 pupils in the UK with dyslexia and a total of some two million people who are severely affected. Yet it still can be difficult for parents to find the right help for their children.
Procter & Gamble Pharmaceuticals (P&GP) acknowledges the publication of the new Technology Appraisal Guidance (TAG 160, for the primary prevention, and 161 for the secondary prevention, of osteoporotic fragility fractures in post-menopausal women) issued by NICE.
Sebastian Stokes -Red Door Communications
NHS staff (in England) are making excellent progress against two key priority areas - to reduce waiting times to 18 weeks and cut Clostridium difficile (C. difficile) infections - statistics released today show.
The ever-evolving healthcare industry has very few constants, and the pharmaceutical sales industry is just another piece of the puzzle that is in the middle of a major transformation. For multinationals, eager to sell their drugs in different countries, juggling between scores of different languages and different laws has always proved to be a major dampener.
This week, organizations around the globe are working to create awareness and educate people about the signs, symptoms, treatment and prevention of one of the leading causes of death and disability––stroke. Wednesday, 29 October officially marks World Stroke Day.
The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the guts incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when blood sugar is low.
Olwen Glynn Owen-Pharmiweb Field Reporter
Current treatments for rheumatoid arthritis (RA) are failing to control patients' pain adequately, and health care professionals are not fully addressing patients' concerns, new research suggests. At the recent Annual Congress of Rheumatology meeting (EULAR) in Paris this summer, findings of a study presented during a UCB-sponsored symposium highlighted a mismatch between perceptions of patients and professionals as to what constitutes effective management of RA
Olwen Glynn Owen - Pharmiweb Field Reporter
Deciding whether or not women with breast cancer require adjuvant chemotherapy after removal of the primary tumour has traditionally been based on a series of prognostic clinical features such as tumour size, lymph node involvement, and other factors. If risk of recurrence is deemed low, adjuvant therapy and its associated toxicity can be avoided. Molecular technology is now available to help clinicians decide on the risks of a particular tumour recurring, based on its genetic fingerprint.
Olwen Glynn Owen - Pharmiweb Field reporter
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her